JP2011504511A - 標的放射線療法 - Google Patents
標的放射線療法 Download PDFInfo
- Publication number
- JP2011504511A JP2011504511A JP2010535181A JP2010535181A JP2011504511A JP 2011504511 A JP2011504511 A JP 2011504511A JP 2010535181 A JP2010535181 A JP 2010535181A JP 2010535181 A JP2010535181 A JP 2010535181A JP 2011504511 A JP2011504511 A JP 2011504511A
- Authority
- JP
- Japan
- Prior art keywords
- opqra
- phenanthro
- perylene
- naphthodianthrone
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001959 radiotherapy Methods 0.000 title abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 132
- 239000004066 vascular targeting agent Substances 0.000 claims abstract description 48
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 230000005855 radiation Effects 0.000 claims abstract description 33
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 32
- 150000003384 small molecules Chemical class 0.000 claims abstract description 31
- 230000017074 necrotic cell death Effects 0.000 claims abstract description 27
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 27
- LEEJQTWXRMXYIB-UHFFFAOYSA-N quinone 7 Chemical class C12=CC=CC(C3=O)=C2C2=C4C3=CC=CC4=C3C4=C2C2=C1C=CC=C2C(=O)C4=CC=C3 LEEJQTWXRMXYIB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 16
- 230000001939 inductive effect Effects 0.000 claims abstract description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 10
- 229910052729 chemical element Inorganic materials 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- -1 phenanthro [1,10,9,8-opqra] perylene-7,14-dione compound Chemical class 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 43
- 229940005608 hypericin Drugs 0.000 claims description 26
- 206010028851 Necrosis Diseases 0.000 claims description 25
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 claims description 25
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 claims description 22
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 claims description 22
- 210000004881 tumor cell Anatomy 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 206010054094 Tumour necrosis Diseases 0.000 claims description 14
- 230000004044 response Effects 0.000 claims description 14
- 230000006378 damage Effects 0.000 claims description 13
- 230000002285 radioactive effect Effects 0.000 claims description 13
- 229910052797 bismuth Inorganic materials 0.000 claims description 12
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 230000002476 tumorcidal effect Effects 0.000 claims description 12
- 229910052727 yttrium Inorganic materials 0.000 claims description 11
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 11
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 9
- 229940002612 prodrug Drugs 0.000 claims description 9
- 239000000651 prodrug Substances 0.000 claims description 9
- YNGACHBZHKWDLZ-UHFFFAOYSA-N Isogymnochrome D Natural products OC1=C(Br)C(O)=C2C(=O)C3=C(O)C(Br)=C(CC(CCC)OS(O)(=O)=O)C4=C3C3=C2C1=C(C(O)=C(Br)C(O)=C1C2=O)C1=C3C1=C2C(O)=C(Br)C(CC(CCC)OS(O)(=O)=O)=C14 YNGACHBZHKWDLZ-UHFFFAOYSA-N 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- YXBUQQDFTYOHQI-UHFFFAOYSA-N Pseudohypericin Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(CO)=C14 YXBUQQDFTYOHQI-UHFFFAOYSA-N 0.000 claims description 7
- 229940120124 dichloroacetate Drugs 0.000 claims description 7
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- 102000004243 Tubulin Human genes 0.000 claims description 6
- 108090000704 Tubulin Proteins 0.000 claims description 6
- 229910052702 rhenium Inorganic materials 0.000 claims description 6
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 230000009696 proliferative response Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229910052692 Dysprosium Inorganic materials 0.000 claims description 4
- 229910052689 Holmium Inorganic materials 0.000 claims description 4
- 102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 claims description 4
- 101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 4
- ROTDMWJNCPPKEJ-UHFFFAOYSA-N gymnochrome B Natural products OC1=C(Br)C(O)=C2C(=O)C3=C(O)C(Br)=C(CC(O)CCC)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=C(Br)C(CC(C)O)=C14 ROTDMWJNCPPKEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 239000002534 radiation-sensitizing agent Substances 0.000 claims description 4
- 238000011287 therapeutic dose Methods 0.000 claims description 4
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims description 3
- 229910052772 Samarium Inorganic materials 0.000 claims description 3
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims description 3
- 229930188281 gymnochrome Natural products 0.000 claims description 3
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 3
- RIWAPWDHHMWTRA-UHFFFAOYSA-N 1,2,3-triiodobenzene Chemical group IC1=CC=CC(I)=C1I RIWAPWDHHMWTRA-UHFFFAOYSA-N 0.000 claims description 2
- DTDZLJHKVNTQGZ-GOSISDBHSA-N AZD7545 Chemical compound C1=CC(C(=O)N(C)C)=CC=C1S(=O)(=O)C1=CC=C(NC(=O)[C@@](C)(O)C(F)(F)F)C(Cl)=C1 DTDZLJHKVNTQGZ-GOSISDBHSA-N 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 150000008062 acetophenones Chemical class 0.000 claims description 2
- 229910000085 borane Inorganic materials 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 2
- 150000002602 lanthanoids Chemical class 0.000 claims description 2
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 229930192524 radicicol Natural products 0.000 claims description 2
- 229940080263 sodium dichloroacetate Drugs 0.000 claims description 2
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 claims description 2
- 125000003047 N-acetyl group Chemical group 0.000 claims 1
- WLZACFNYSRUSIX-UHFFFAOYSA-N Radicicol A Natural products C1=CCC(O)C(O)C(=O)C=CCC(C)OC(=O)C=2C1=C(OC)C(OC)=CC=2O WLZACFNYSRUSIX-UHFFFAOYSA-N 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000007674 radiofrequency ablation Methods 0.000 abstract description 19
- 238000002512 chemotherapy Methods 0.000 abstract description 14
- 238000002679 ablation Methods 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 238000002347 injection Methods 0.000 abstract description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 238000000315 cryotherapy Methods 0.000 abstract description 2
- 239000002254 cytotoxic agent Substances 0.000 abstract description 2
- 231100000599 cytotoxic agent Toxicity 0.000 abstract description 2
- 238000002647 laser therapy Methods 0.000 abstract description 2
- 238000002604 ultrasonography Methods 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 13
- 239000002253 acid Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- VXNQMUVMEIGUJW-XNOMRPDFSA-L disodium;[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] phosphate Chemical compound [Na+].[Na+].C1=C(OP([O-])([O-])=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 VXNQMUVMEIGUJW-XNOMRPDFSA-L 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000001338 necrotic effect Effects 0.000 description 9
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 8
- 229960005537 combretastatin A-4 Drugs 0.000 description 8
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 8
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 7
- 229910052688 Gadolinium Inorganic materials 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000000637 radiosensitizating effect Effects 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 4
- 238000011319 anticancer therapy Methods 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002428 photodynamic therapy Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 235000017309 Hypericum perforatum Nutrition 0.000 description 3
- 244000141009 Hypericum perforatum Species 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 150000004814 combretastatins Chemical class 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000000147 enterotoxin Substances 0.000 description 3
- 231100000655 enterotoxin Toxicity 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 208000037843 metastatic solid tumor Diseases 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229940109328 photofrin Drugs 0.000 description 3
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 2
- FRDONCXLMWOCKJ-UHFFFAOYSA-N 5,7,11,13,17,19,23,25-octahydroxy-15-(4-hydroxyphenyl)-6,24-di(propan-2-yl)octacyclo[14.11.1.12,10.03,8.04,26.020,28.022,27.014,29]nonacosa-1,3,5,7,10(29),11,13,16,18,20(28),22,24,26-tridecaene-9,21-dione Chemical compound C12=C(O)C=C(O)C(C3=O)=C2C2=C4C3=C(O)C(C(C)C)=C(O)C4=C3C(O)=C(C(C)C)C(O)=C(C(C4=C(O)C=C5O)=O)C3=C2C4=C5C1C1=CC=C(O)C=C1 FRDONCXLMWOCKJ-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- GAWAYYRQGQZKCR-REOHCLBHSA-N (S)-2-chloropropanoic acid Chemical compound C[C@H](Cl)C(O)=O GAWAYYRQGQZKCR-REOHCLBHSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical class C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical class C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- DFDJVFYYDGMDTB-BIYVAJLZSA-N 1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[[(3s,4r,5s)-3,4,5,6-tetrahydroxy-2-oxohexanoyl]amino]benzene-1,3-dicarboxamide Chemical compound OCC(O)CNC(=O)C1=C(I)C(NC(=O)C(=O)[C@@H](O)[C@H](O)[C@@H](O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I DFDJVFYYDGMDTB-BIYVAJLZSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- GAWAYYRQGQZKCR-UHFFFAOYSA-N 2-chloropropionic acid Chemical compound CC(Cl)C(O)=O GAWAYYRQGQZKCR-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- MVUKOPBAEUTPRV-UHFFFAOYSA-N 3-[2-[2-[2-carboxyethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]-4-(4-ethoxyphenyl)butanoic acid Chemical compound CCOC1=CC=C(CC(CC(O)=O)N(CCN(CCN(CCC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)C=C1 MVUKOPBAEUTPRV-UHFFFAOYSA-N 0.000 description 1
- NWFRWPDAHVNCSL-UHFFFAOYSA-N 3-[2-[2-[2-carboxyethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]-4-(4-phenylmethoxyphenyl)butanoic acid Chemical compound C1=CC(CC(CC(O)=O)N(CC(O)=O)CCN(CCN(CCC(=O)O)CC(O)=O)CC(O)=O)=CC=C1OCC1=CC=CC=C1 NWFRWPDAHVNCSL-UHFFFAOYSA-N 0.000 description 1
- SDHYPWHTBKHDJW-UHFFFAOYSA-N 3-[2-[2-[2-carboxyethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]-4-phenylmethoxybutanoic acid Chemical compound OC(=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)C(CC(O)=O)COCC1=CC=CC=C1 SDHYPWHTBKHDJW-UHFFFAOYSA-N 0.000 description 1
- IRYYCWRQWAKJMU-WZTVWXICSA-N 3-[acetyl(ethyl)amino]-5-[3-[3-[3-[acetyl(ethyl)amino]-5-carboxy-2,4,6-triiodoanilino]-3-oxopropyl]sulfonylpropanoylamino]-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)C1=C(I)C(N(C(C)=O)CC)=C(I)C(NC(=O)CCS(=O)(=O)CCC(=O)NC=2C(=C(C(O)=O)C(I)=C(N(CC)C(C)=O)C=2I)I)=C1I IRYYCWRQWAKJMU-WZTVWXICSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- XPJWBEJPSVRTAD-UHFFFAOYSA-N 4-(4-butylphenyl)-3-[2-[2-[2-carboxyethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]butanoic acid Chemical compound CCCCC1=CC=C(CC(CC(O)=O)N(CCN(CCN(CCC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)C=C1 XPJWBEJPSVRTAD-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- OQHLOKBHRXMXLD-UHFFFAOYSA-N 5-[3-[3-[3,5-bis[2,3-dihydroxypropyl(methyl)carbamoyl]-2,4,6-triiodoanilino]-3-oxopropyl]sulfanylpropanoylamino]-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1-n,3-n-dimethylbenzene-1,3-dicarboxamide Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(C(=O)N(CC(O)CO)C)=C(I)C(NC(=O)CCSCCC(=O)NC=2C(=C(C(=O)N(C)CC(O)CO)C(I)=C(C(=O)N(C)CC(O)CO)C=2I)I)=C1I OQHLOKBHRXMXLD-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- YEEGWNXDUZONAA-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-gallabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Ga+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YEEGWNXDUZONAA-UHFFFAOYSA-K 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KMBGIJRUEPNHHZ-UHFFFAOYSA-N C(CNCCNCCN(CCC(=O)O)CC(=O)O)C(=O)O Chemical compound C(CNCCNCCN(CCC(=O)O)CC(=O)O)C(=O)O KMBGIJRUEPNHHZ-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical class C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 241000221032 Combretaceae Species 0.000 description 1
- 241000375691 Combretum caffrum Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930184591 Fringelite Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- WWVAPFRKZMUPHZ-UHFFFAOYSA-N Iodoxamic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCOCCOCCOCCOCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I WWVAPFRKZMUPHZ-UHFFFAOYSA-N 0.000 description 1
- OIRFJRBSRORBCM-UHFFFAOYSA-N Iopanoic acid Chemical compound CCC(C(O)=O)CC1=C(I)C=C(I)C(N)=C1I OIRFJRBSRORBCM-UHFFFAOYSA-N 0.000 description 1
- YQNFBOJPTAXAKV-OMCISZLKSA-N Iopodic acid Chemical compound CN(C)\C=N\C1=C(I)C=C(I)C(CCC(O)=O)=C1I YQNFBOJPTAXAKV-OMCISZLKSA-N 0.000 description 1
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
- JXMIBUGMYLQZGO-UHFFFAOYSA-N Iotroxic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)COCCOCCOCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I JXMIBUGMYLQZGO-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 241000577218 Phenes Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- ROSXARVHJNYYDO-UHFFFAOYSA-N Propyliodone Chemical compound CCCOC(=O)CN1C=C(I)C(=O)C(I)=C1 ROSXARVHJNYYDO-UHFFFAOYSA-N 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- WDOGQTQEKVLZIJ-WAYWQWQTSA-L [2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] phosphate Chemical compound C1=C(OP([O-])([O-])=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-L 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- FFINMCNLQNTKLU-UHFFFAOYSA-N adipiodone Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I FFINMCNLQNTKLU-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 150000001553 barium compounds Chemical class 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229930194430 blepharismin Natural products 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 150000001788 chalcone derivatives Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011498 curative surgery Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000010013 cytotoxic mechanism Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- PBWZKZYHONABLN-UHFFFAOYSA-M difluoroacetate Chemical compound [O-]C(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-M 0.000 description 1
- SLYTULCOCGSBBJ-UHFFFAOYSA-I disodium;2-[[2-[bis(carboxylatomethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+) Chemical compound [Na+].[Na+].[Gd+3].CCOC1=CC=C(CC(CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)N(CC([O-])=O)CC([O-])=O)C=C1 SLYTULCOCGSBBJ-UHFFFAOYSA-I 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 230000005264 electron capture Effects 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229940011957 ethiodized oil Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002259 gallium compounds Chemical class 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 description 1
- 229960004901 iodamide Drugs 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 229940029355 iodipamide Drugs 0.000 description 1
- 229960002487 iodoxamic acid Drugs 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- 229960002979 iopanoic acid Drugs 0.000 description 1
- RXUVYYAWLAIABB-UHFFFAOYSA-N iosefamic acid Chemical compound OC(=O)C1=C(I)C(C(=O)NC)=C(I)C(NC(=O)CCCCCCCCC(=O)NC=2C(=C(C(=O)NC)C(I)=C(C(O)=O)C=2I)I)=C1I RXUVYYAWLAIABB-UHFFFAOYSA-N 0.000 description 1
- 229950009516 iosefamic acid Drugs 0.000 description 1
- 229960000929 iotalamic acid Drugs 0.000 description 1
- 229950011097 iotasul Drugs 0.000 description 1
- 229960000506 iotroxic acid Drugs 0.000 description 1
- 229960001707 ioxaglic acid Drugs 0.000 description 1
- TYYBFXNZMFNZJT-UHFFFAOYSA-N ioxaglic acid Chemical compound CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I TYYBFXNZMFNZJT-UHFFFAOYSA-N 0.000 description 1
- 229940029409 ipodate Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
- 229960004712 metrizoic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- WJJZQSCOTJYYSP-INIZCTEOSA-N n-[(7s)-9-hydroxy-1,2,3-trimethoxy-6,7-dihydro-5h-dibenzo[5,3-b:1',2'-e][7]annulen-7-yl]acetamide Chemical compound C1C[C@H](NC(C)=O)C2=CC(O)=CC=C2C2=C1C=C(OC)C(OC)=C2OC WJJZQSCOTJYYSP-INIZCTEOSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950005848 olivomycin Drugs 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003927 propyliodone Drugs 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003476 thallium compounds Chemical class 0.000 description 1
- GBECUEIQVRDUKB-UHFFFAOYSA-M thallium monochloride Chemical compound [Tl]Cl GBECUEIQVRDUKB-UHFFFAOYSA-M 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000001731 vasotoxic effect Effects 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
本発明は、治療学的に標識されたナフトジアントロン(napthodianthrone)またはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物に関する。これらの化合物は、化学元素または同位元素を含み、当該化学元素または当該同位元素は、不安定な核を有し、壊死を誘発する抗腫瘍療法を受けた温血動物の治療可能性を高めるための標的放射線療法において使用するために、安定した形態に向かう核崩壊の間にわたって、隣接する細胞または組織を破壊するに十分な放射線を放出する。本発明の特別な利点は、ナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物のグループの、治療学的に放射標識された壊死親和性(necrosis-avid)小分子を1回以上静脈投与することによって、例えば脈管標的剤(VTA)等の壊死を誘発する抗腫瘍療法に耐性を示す、生存能力のある辺縁(rim)または腫瘍の残りが、補完的に治療され得ることである。上記ナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物は、根治治療の効果を達成するために、前もって形成された腫瘍内の壊死において選択的に蓄積し、隣接する生存能力のある腫瘍細胞に対して放射線を放出する。
世界的に見て、がんは、依然として最も命に関わる疾患のままである。従来の放射線療法および化学療法は、通常、腫瘍成長の速度を落とし、患者生存を引き伸ばすためだけの苦痛緩和剤と考えられているが、全身性の副作用という代償を払う。最善の治療の選択肢は根治手術であるが、腫瘍の不利な局在、腫瘍の病期および腫瘍の大きさによって、限られた数の患者のみが適している。さらに、部分的な切除後の臓器の限られた機能の保存は、より高い術後リスクとも関連している。社会的共同体、健康管理機関および医学専門家は、がんと闘うための新しい治療の研究および開発において非常に努力している。新しく開発された抗がん治療の中で、脈管標的剤(VTA)は、新生血管の内皮細胞の細胞骨格を選択的に崩壊させ、腫瘍性の血液の供給の遮断並びにその後の腫瘍細胞の飢餓および腫瘍細胞の死をもたらす[Thorpe PE. Clin Cancer Res. 2004; 10: 415-27];ラジオ波焼灼療法(REA)は、低侵襲的な手段であり、特に、孤立した腫瘍を治療するために、RFエネルギーから変換された熱を用いて生物組織を破壊する[Ni Y, et al; Abdominal Imaging 2005; 30: 381-400];光線力学療法(PDT)は、ある波長の光照射と薬剤または光線感光物質の投与とを組み合わせて、生成された細胞毒性の種によってがん細胞を殺す[Pass H, JNatl Cancer Inst 1993; 85: 443-56]。これらの治療に共通な顕著な結果は、腫瘍の壊死を引き起こすことである。他方では、AZD7545、ジクロロ酢酸塩(DCA)、ジクロロ酢酸ナトリウム、トリクロロ酢酸塩、ジフルオロ酢酸塩、2−クロロプロピオン酸、2,2’−ジクロロプロピオン酸、クロロプロピオン酸、ハロゲン化アセトフェノン阻害剤、ラディシコールオキシムまたはラディシコールといったピルビン酸デヒドロゲナーゼキナーゼ阻害剤の使用は、がん腫瘍において解糖からグルコース酸化促進性アポトーシスへと代謝を切り替えるミトコンドリアのピルビン酸デヒドロゲナーゼキナーゼ(PDK)を阻害する[Alla Klyuyeva et al. FEBS Lett. 2007 June 26; 581(16): 2988-2992 and Biochem.J. 329 191. Bonnet et al (2007)*。
本発明は、化学療法(例えば脈管標的剤またはVTAによる治療法)、あるいは物理学的にもしくは化学的に誘発された焼灼(例えばラジオ波焼灼またはRFAによって)または任意の他の既存の効果的な非外科的抗がん療法による、初期の固形腫瘍または転移性固形腫瘍の殺腫瘍治療の効率および有効性を改善するための薬剤において使用するための放射性薬剤の組成を、一部において対象としている。より具体的には、本発明は、不完全な抗腫瘍治療に対する応答としての腫瘍細胞増殖を防ぐために、または物理学的にもしくは化学的に誘発された腫瘍の破壊の後に固形腫瘍における腫瘍細胞が再増殖することを防ぐために、または化学療法誘発性の腫瘍の収縮の後で腫瘍が再成長することを防ぐために、または初期の固形腫瘍もしくは転移性の固形腫瘍またはそのような腫瘍に隣接する局所領域の組織において残存している抗腫瘍剤耐性のがん細胞を取り除くために、薬剤において使用するための壊死親和性の化学化合物を形成するための治療学的に放射性核種標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物を対象としている。
Claims (37)
- 壊死誘発性の抗腫瘍療法を受けている温血動物の治療可能性を高めるための壊死標的療法において用いるための、治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 上記ナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物は、ヒペリシン、偽ヒペリシン、ステントリン、フリンゲリト、ギムノクロームB、ギムノクロームD、イソギムノクロームDおよびブレファリスミンからなる群の化合物である、請求項1に記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 上記治療学的な標識は、153サマリウム、156ホルミウム、165ジスプロシウム、203鉛、186レニウム、188レニウム、211ビスマス、212ビスマス、213ビスマス、および214ビスマス、153Sm、159Gd、186Re、166Ho、88イットリウム、90イットリウム、91イットリウム、89イットリウム並びに131ヨウ素からなる群からの放射性放射体である、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物は、ヨウ素−131−ヒペリシンである、前請求項のいずれか。
- 上記治療学的な標識は、不安定な核を有し、かつ、安定した形態に向かう核崩壊の間にわたって、隣接している細胞または組織を局所領域的に破壊するに十分な放射線を放出する放射性核種である、請求項1に記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 腫瘍の再発を防ぐための、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 壊死誘発性抗腫瘍療法に対して耐性である、残存している生存能力のある腫瘍細胞の、腫瘍の損傷、腫瘍の焼灼または腫瘍の破壊に対する応答としての上記増殖反応を阻止するための、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 上記治療学的な標識は、25〜350MBq/kgの放射線量を得るための量である、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 脈管標的剤と(一緒にまたは順に)組み合わせた治療における使用のための、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 腫瘍の再発を防ぐために、上記治療学的な標識は、25〜350MBq/kgの放射線量を得るための量であり、5〜100mg/kgの投与量を得るための量における脈管標的剤である、請求項7および8に記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- AZD7545、ジクロロ酢酸塩(DCA)、ジクロロ酢酸ナトリウム、ハロゲン化アセトフェノン阻害剤、ラディシコールオキシムまたはラディシコールのような、ピルビン酸デヒドロゲナーゼキナーゼ阻害剤を用いる治療と(一緒にまたは順番に)組み合わせて使用するための、請求項1〜7のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 上記放射性放射体は、放射性ランタニドの群から選択される放射性同位体または放射性元素から成る群から選択される、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 上記治療学的な標識は、放射性イットリウムまたは放射性レニウムである、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 上記治療学的な標識は、放射性ハロゲンである、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 上記治療学的な標識は、α放射体、β放射体およびγ放射体からなる群の放射性放射体である、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 治療学的な標識は、β放射体であり、当該β放射体のβエネルギーは、>0.1MeVであり、上記β放射体は1日を越える放射性核種の半減期を有する、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 上記治療学的な標識は、β放射体であり、当該β放射体のβエネルギーは、>0.1MeVであり、上記β放射体は、1週間を越える放射性核種の半減期を有している、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物は、放射線増感剤をさらに含有している、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 上記放射線増感剤は、トリヨードベンゼン成分、ボラン成分またはカルボラン成分である、請求項14に記載の治療学的に標識された小分子壊死親和性化学化合物。
- 上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオンは、1以上のジクロロ酢酸塩成分を有している、前請求項のいずれかに記載の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物。
- 前請求項に記載の治療において使用するための、上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物および薬学的に許容され得る担体を含有している、薬学的組成物。
- (a)殺腫瘍性の化合物、化学療法剤、抗腫瘍剤および脈管標的剤からなる群の第1の薬剤と、
(b)腫瘍の壊死を誘発し、その結果として、壊死誘発性抗腫瘍療法に耐性のある、生存能力のある腫瘍細胞の腫瘍の損傷、腫瘍の焼灼または腫瘍の破壊への応答としての増殖反応を防ぐための治療において使用するための、不安定な核を有し、かつ、安定した形態に向かう核崩壊の間にわたって、隣接している細胞または組織を局所領域的に破壊するに十分な放射線を放出する化学元素または同位体を含有している、第2の治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物と、
を含有している、キット。 - 上記第1の薬剤は、脈管標的剤、コンブレタスタチンもしくはその類似体、またはその薬学的に許容され得る塩である、請求項22のキット。
- 上記第1の薬剤は、チューブリン結合剤の水溶性リン酸塩プロドラッグであるZD6126(N−アセチルコルヒノール)である、請求項22のキット。
- 上記第1の薬剤は、コンブレタスタチンA−4のリン酸塩プロドラッグの塩である、請求項22のキット。
- 上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物は、ヒペリシン、偽ヒペリシン、ステントリン、フリンゲリト、ギムノクロームB、ギムノクロームD、イソギムノクロームDおよびブレファリスミンからなる群の化合物である、請求項22のキット。
- 上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物は、治療において25〜350MBq/kgを供給するために、放射性標識を含有していた、請求項22から26のキット。
- 上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物は、治療において35〜250MBq/kgを供給するために、放射性標識を含有している、請求項22から27のキット。
- 上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物は、治療において50〜200MBq/kgを供給するために、放射性標識を含有している、請求項22から28のキット。
- 上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物は、5000MBq〜60000MBqの放射線量を有している、請求項22から29のキット。
- 上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物は、5000MBq〜20000MBqの放射線量を有している、請求項22から30のキット。
- 上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物は、25〜350MBq/kgの治療放射線量を得るための量における放射線標識されたヒペリシンおよび5〜200mg/kgの治療投与量、好ましくは5〜50mg/kgの治療投与量を得るための量における上記脈管標的剤である、請求項22から31のキット。
- 上記治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物および上記脈管標的剤は、腫瘍壊死の誘発と腫瘍の再発の予防とを(一緒にまたは順番に)組み合わせた治療において用いるためのものである、請求項22から32のキット。
- 必要とする患者において腫瘍の壊死を誘発し、腫瘍の再発を防ぐ治療の方法であり、
上記方法は、上記患者に、
(a)殺腫瘍性の化合物、化学療法剤、抗腫瘍剤および脈管標的剤からなる群の第1の薬剤と、
(b)不安定な核を有し、かつ、安定した形態に向かう核崩壊の間にわたって、隣接している細胞または組織を局所領域的に破壊するに十分な放射線を放出する化学元素または同位体を含有している、治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物である、第2の薬剤と、
を投与することを包含し、
上記第1および上記第2の化合物は、ともに上記疾患を処置するに十分な量において、同時に投与されるか、またはお互いの投与の1日から3日間以内に投与される。 - 必要とする患者において腫瘍の壊死を誘発し、局所の腫瘍の再成長または遠位の転移腫瘍の再成長を防ぐ治療の方法であり、
上記方法は、上記患者に、
(a)殺腫瘍性の化合物、化学療法剤、抗腫瘍剤および脈管標的剤からなる群の第1の薬剤と、
(b)不安定な核を有し、かつ、安定した形態に向かう核崩壊の間にわたって、隣接している細胞または組織を局所領域的に破壊するに十分な放射線を放出する化学元素または同位体を含有している、治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物である、第2の薬剤と、
を投与することを包含し、
上記第1および上記第2の化合物は、ともに上記疾患を処置するに十分な量において、同時に投与されるか、またはお互いの投与の1日から3日間以内に投与される。 - 必要とする患者において腫瘍の壊死を誘発し、腫瘍の損傷、腫瘍の焼灼または腫瘍の破壊に対する応答としての、壊死誘発性抗腫瘍療法に対して耐性のある生存能力のある腫瘍細胞の続く増殖反応を阻害する治療の方法であり、
上記方法は、上記患者に、
(a)殺腫瘍性の化合物、化学療法剤、抗腫瘍剤および脈管標的剤からなる群の第1の薬剤と、
(b)不安定な核を有し、かつ、安定した形態に向かう核崩壊の間にわたって、隣接している細胞または組織を局所領域的に破壊するに十分な放射線を放出する化学元素または同位体を含有している、治療学的に標識されたナフトジアントロンまたはフェナントロ[1,10,9,8−opqra]ペリレン−7,14−ジオン化合物である、第2の薬剤と、
を投与することを包含し、
上記第1および上記第2の化合物は、ともに上記疾患を処置するに十分な量において、同時に投与されるか、またはお互いの投与の1日から3日間以内に投与される。 - 上記第2の薬剤を用いた少なくとも1以上の治療工程が続く、上記の請求項のいずれかに記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0723124.4 | 2007-11-26 | ||
GBGB0723124.4A GB0723124D0 (en) | 2007-11-26 | 2007-11-26 | Targeted radiotherapy |
PCT/BE2008/000099 WO2009067767A2 (en) | 2007-11-26 | 2008-11-26 | Targeted radiotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011504511A true JP2011504511A (ja) | 2011-02-10 |
JP5757737B2 JP5757737B2 (ja) | 2015-07-29 |
Family
ID=38926044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010535181A Active JP5757737B2 (ja) | 2007-11-26 | 2008-11-26 | 標的放射線療法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8741262B2 (ja) |
EP (1) | EP2219683B1 (ja) |
JP (1) | JP5757737B2 (ja) |
KR (1) | KR20100102621A (ja) |
CN (1) | CN101925367B (ja) |
AU (1) | AU2008329573B2 (ja) |
CA (1) | CA2706597C (ja) |
DK (1) | DK2219683T3 (ja) |
ES (1) | ES2388957T3 (ja) |
GB (1) | GB0723124D0 (ja) |
HK (1) | HK1147684A1 (ja) |
IL (1) | IL205970A0 (ja) |
PL (1) | PL2219683T3 (ja) |
PT (1) | PT2219683E (ja) |
WO (1) | WO2009067767A2 (ja) |
ZA (1) | ZA201003706B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8741262B2 (en) | 2007-11-26 | 2014-06-03 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Targeted radiotherapy |
JP2016525079A (ja) * | 2013-07-01 | 2016-08-22 | ジ・オーストラリアン・ナショナル・ユニバーシティー | 放射標識物質 |
JP2020526518A (ja) * | 2017-07-07 | 2020-08-31 | カトリック ユニヴェルシテット ルーヴェン | 無血管性または乏血管性微小腫瘍の治療 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102430134B (zh) * | 2011-12-08 | 2014-07-09 | 江苏省中医药研究院 | 放射性同位素标记的日照蒽酮类或萘并二蒽酮类化合物用于制备抗结核药物应用 |
CN102488910B (zh) * | 2011-12-29 | 2013-10-02 | 江苏省中医药研究院 | 放射性同位素标记的日照蒽酮类化合物用于制备抗肿瘤药物用途 |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
CN102526766B (zh) * | 2012-02-07 | 2013-06-12 | 江苏省中医药研究院 | 萘并二蒽酮类化合物及其盐在制备胆道及胆石显像剂中应用 |
CN104096234B (zh) * | 2013-04-02 | 2017-08-29 | 江苏省中医药研究院 | 胆酸盐溶液在制备萘并二蒽酮类药物制剂中的应用 |
CA2935743A1 (en) | 2014-01-04 | 2015-07-09 | Vijay Agarwal | Device and method for use of photodynamic therapy |
US10335608B2 (en) | 2016-04-20 | 2019-07-02 | Theralase Technologies, Inc. | Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics |
RU2699558C2 (ru) * | 2018-10-05 | 2019-09-06 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ Радиологии" Минздрава России РФ) | Средство для таргетной терапии злокачественных новообразований |
CA3128067A1 (en) | 2019-02-13 | 2020-08-20 | Alpheus Medical, Inc. | Non-invasive sonodynamic therapy |
CN109761958B (zh) * | 2019-03-04 | 2020-04-28 | 中国药科大学 | 法舒地尔复合盐及其制备方法和用途 |
KR102133823B1 (ko) * | 2019-06-12 | 2020-07-15 | 한국원자력연구원 | 퀴논 화합물을 이용한 방사성 원소의 표지방법, 방사성 표지화합물 및 이를 포함하는 방사성 원소 표지 키트 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002538201A (ja) * | 1999-03-11 | 2002-11-12 | カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント | 癌を診断および治療する手段 |
WO2006002122A2 (en) * | 2004-06-17 | 2006-01-05 | Anazaohealth Corporation | Stabilized and lyophilized radiopharmaceutical agents |
WO2007002500A1 (en) * | 2005-06-24 | 2007-01-04 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2189967A1 (en) | 1994-05-11 | 1995-11-23 | Guy Jacques Felix Marchal | The use of porphyrin-complex or expanded porphyrin-complex compounds as localization diagnosticum for infarction or necrosis |
DE19824653A1 (de) | 1998-02-25 | 1999-08-26 | Schering Ag | Nekrose-affine Verbindungen und ihre Verwendung zur Herstellung von Präparaten zur Pharmakotherapie |
US20050013778A1 (en) * | 2001-04-03 | 2005-01-20 | Theseus Imaging Corporation | Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death |
GB0317467D0 (en) | 2003-07-25 | 2003-08-27 | Leuven K U Res & Dev | Tissue infraction and necrosis specific compounds |
TW200716141A (en) * | 2005-05-05 | 2007-05-01 | Combinatorx Inc | Compositions and methods for treatment for neoplasms |
GB0723124D0 (en) | 2007-11-26 | 2008-01-02 | Univ Leuven Kath | Targeted radiotherapy |
-
2007
- 2007-11-26 GB GBGB0723124.4A patent/GB0723124D0/en not_active Ceased
-
2008
- 2008-11-26 US US12/744,798 patent/US8741262B2/en active Active
- 2008-11-26 CA CA2706597A patent/CA2706597C/en active Active
- 2008-11-26 EP EP08854013A patent/EP2219683B1/en active Active
- 2008-11-26 PT PT08854013T patent/PT2219683E/pt unknown
- 2008-11-26 AU AU2008329573A patent/AU2008329573B2/en active Active
- 2008-11-26 ES ES08854013T patent/ES2388957T3/es active Active
- 2008-11-26 JP JP2010535181A patent/JP5757737B2/ja active Active
- 2008-11-26 CN CN200880125605.6A patent/CN101925367B/zh active Active
- 2008-11-26 WO PCT/BE2008/000099 patent/WO2009067767A2/en active Application Filing
- 2008-11-26 DK DK08854013.3T patent/DK2219683T3/da active
- 2008-11-26 KR KR1020107014126A patent/KR20100102621A/ko not_active Application Discontinuation
- 2008-11-26 PL PL08854013T patent/PL2219683T3/pl unknown
-
2010
- 2010-05-25 ZA ZA2010/03706A patent/ZA201003706B/en unknown
- 2010-05-26 IL IL205970A patent/IL205970A0/en unknown
-
2011
- 2011-02-23 HK HK11101780.9A patent/HK1147684A1/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002538201A (ja) * | 1999-03-11 | 2002-11-12 | カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント | 癌を診断および治療する手段 |
WO2006002122A2 (en) * | 2004-06-17 | 2006-01-05 | Anazaohealth Corporation | Stabilized and lyophilized radiopharmaceutical agents |
WO2007002500A1 (en) * | 2005-06-24 | 2007-01-04 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
Non-Patent Citations (4)
Title |
---|
JPN6013024227; Photochemistry and Photobiology Vol.78, 2003, p.278-282 * |
JPN6013024229; Contrast Media and Molecular Imaging Vol.2, 200706, p.113-119 * |
JPN6013024230; Bulletin of the Korean Chemical Society Vol.25, 2004, p.1147-1150 * |
JPN6013024233; Bioorganic and Medicinal Chemistry Letters Vol.17, 200704, p.4001-4005 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8741262B2 (en) | 2007-11-26 | 2014-06-03 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Targeted radiotherapy |
JP2016525079A (ja) * | 2013-07-01 | 2016-08-22 | ジ・オーストラリアン・ナショナル・ユニバーシティー | 放射標識物質 |
JP2020526518A (ja) * | 2017-07-07 | 2020-08-31 | カトリック ユニヴェルシテット ルーヴェン | 無血管性または乏血管性微小腫瘍の治療 |
JP7360169B2 (ja) | 2017-07-07 | 2023-10-12 | カトリック ユニヴェルシテット ルーヴェン | 無血管性または乏血管性微小腫瘍の治療 |
Also Published As
Publication number | Publication date |
---|---|
KR20100102621A (ko) | 2010-09-24 |
ES2388957T3 (es) | 2012-10-22 |
CA2706597A1 (en) | 2009-06-04 |
JP5757737B2 (ja) | 2015-07-29 |
PT2219683E (pt) | 2012-09-04 |
DK2219683T3 (da) | 2012-09-10 |
CN101925367B (zh) | 2017-05-31 |
AU2008329573A1 (en) | 2009-06-04 |
AU2008329573B2 (en) | 2014-02-13 |
CA2706597C (en) | 2016-03-15 |
HK1147684A1 (en) | 2011-08-19 |
CN101925367A (zh) | 2010-12-22 |
WO2009067767A2 (en) | 2009-06-04 |
US20110038795A1 (en) | 2011-02-17 |
ZA201003706B (en) | 2011-02-23 |
US8741262B2 (en) | 2014-06-03 |
EP2219683B1 (en) | 2012-05-30 |
EP2219683A2 (en) | 2010-08-25 |
IL205970A0 (en) | 2010-11-30 |
GB0723124D0 (en) | 2008-01-02 |
PL2219683T3 (pl) | 2012-12-31 |
WO2009067767A3 (en) | 2010-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5757737B2 (ja) | 標的放射線療法 | |
CA2660507C (en) | Targeted nanoparticles for cancer diagnosis and treatment | |
Larsen et al. | 221At-and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation | |
Wang et al. | Biodistribution of rhenium-188 Lipiodol infused via the hepatic artery of rats with hepatic tumours | |
Lambert et al. | Treatment of hepatocellular carcinoma by means of radiopharmaceuticals | |
Babbar et al. | Evaluation of 99mTc-labeled photosan-3, a hematoporphyrin derivative, as a potential radiopharmaceutical for tumor scintigraphy | |
JP6356854B2 (ja) | 放射性構成物およびそれらの治療的使用方法 | |
US20170348441A1 (en) | Therapy of malignant neoplasias | |
Link et al. | 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of micrometastases | |
CA2701537A1 (en) | Compositions for treatment of tumors by direct administration of a radioisotope | |
CN109789207A (zh) | 用于原位免疫调节的癌症疫苗接种的靶向放射治疗螯合物 | |
McLendon et al. | Radiotoxicity of systemically administered [211At] astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis | |
Novell et al. | Therapeutic aspects of radio-isotopes in hepatobiliary malignancy | |
Lepareur et al. | Transarterial radionuclide therapy with 188Re-labelled lipiodol | |
US20210236664A1 (en) | Alpha particle formulations for treatment of solid tumors | |
Bhargavi et al. | Transarterial radioembolization with Iodine-131-Lipiodol for hepatic metastases from gastrointestinal malignancies–Experience in tertiary care oncology center in India | |
Lin et al. | A comparison of Re-188-MN-16ET-lipiodol and transcatheter arterial chemoembolization in the treatment of hepatoma: an animal study | |
ES2341575T3 (es) | Terapia de neoplasias malignas. | |
Jalilian et al. | Preparation, biodistribution and stability of [65Zn] bleomycin complex | |
Towu et al. | In-vitro uptake of radioactive lipiodol I-131 and I-125 by hepatoblastoma: implications for targeted radiotherapy | |
Ando et al. | The Studies of in Vivo Distributions of Radioiodinated Cobalt-bleomycin in Tumor-bearing Animals by the Whole Body Autoradiography | |
Ståhlberg | Estramustine and its Derivatives in Potentiating Radiotherapy of Prostate Cancer | |
Maini et al. | 153Sm-EDTM for Bone Pain Treatment in Skeletal Metastases | |
Wang et al. | The Status and Prospects of Radiopharmaceutical Research for Targeted Radiotherapy in Taiwan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111021 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130521 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130806 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130924 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140509 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140724 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150512 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150602 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5757737 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |